Gilles Nobecourt Overview

  • Primary Position
  • Partner, Andera...

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 5

  • Med. Deal Size

  • Med. Valuation

Gilles Nobecourt General Information

Biography

Dr. Gilles Nobecourt serves as a Partner of the Andera Life Science team at Andera Partners. He also serves as a Board Administrator at Genkyotex. He serves as the Board Member at Crescendo Biologics. He served as a Board Member at Complexa. He also served as a Partner at Edmond de Rothschild Asset Management (Suisse). Previously, he joined the recruitment firm Russell Reynolds Associates as a consultant for pharmaceutical and biotechnology companies. Before that, he was Vice President of Global Operations of RPR Gencell, the San Francisco-based biotechnology division of Sanofi-aventis (previously Rhône Poulenc Rorer), and acted as Director of a commercial division in Mexico. Mr. Nobecourt began his career by serving in various government appointments in France, including Advisor to the Prime Minister, and Advisor to the Minister for Research and Industry. He serves as a Board member at Inotrem and GamaMabs. Mr. Nobecourt is a graduate of the Institut d 'Études Politiques in Paris, holds a master's degree in Applied Economics, and attended General Management training at the University of Stanford Global School of Business.

Contact Information

Primary Position
Partner, Andera Life Science team, Andera Partners
Education
Stanford University, Master's
Institut d'Etudes Politiques de Paris, Graduate
Gender
Male
Email
g.
Phone
+33 01
Address
  • 2, place Rio de Janeiro
  • 75008 Paris
  • France
+33 01

Gilles Nobecourt Positions (1)

Firm name Firm type Title Location Industry Since
Andera Partners Investor Partner, Andera Life Science team Paris, France PE/Buyout

Gilles Nobecourt Board Seats (5)

Company Industry Ownership Status Financing Status Location Since
Complix Drug Discovery Privately Held (backing) Venture Capital-Backed Diepenbeek, Belgium
Crescendo Biologics Drug Discovery Privately Held (backing) Venture Capital-Backed Cambridge, United Kingdom
Evommune Drug Discovery Privately Held (backing) Venture Capital-Backed Palo Alto, CA
GamaMabs Pharma Drug Discovery Privately Held (backing) Venture Capital-Backed Toulouse, France
Inotrem Drug Discovery Privately Held (backing) Venture Capital-Backed Paris, France

Gilles Nobecourt Lead Partner on Deals (21)

Gilles Nobecourt has been the lead partner on 21 deals. Their latest deal was with Crescendo Biologics, a drug discovery company. The deal was made for on 24-Jul-2023.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Crescendo Biologics 24-Jul-2023 Later Stage VC Completed Drug Discovery Cambridge, United Kingdom
Evommune 28-Jun-2023 Completed Drug Discovery Palo Alto, CA
Evommune 29-Oct-2021 Completed Drug Discovery Palo Alto, CA
Inotrem 11-Feb-2020 Completed Drug Discovery Paris, France
Crescendo Biologics 30-Apr-2018 Completed Drug Discovery Cambridge, United Kingdom
Complexa 26-Jul-2017 Completed Biotechnology Berwyn, PA
Pacifix 27-Jan-2016 Completed Other Consumer Durables Melbourne, Australia
GamaMabs Pharma 15-Dec-2015 Completed Drug Discovery Toulouse, France
Complix 10-Apr-2015 Later Stage VC (Series B) Completed Drug Discovery Diepenbeek, Belgium
Genkyotex 07-Jan-2015 Later Stage VC (Series D) Completed Drug Discovery Saint-Julien- en-Genevois, France

Gilles Nobecourt Network (225)

Board Members (101)

Name Company Representing Location From
Eric Viaud Genkyotex Self Saint-Julien- en-Genevois, France
Martine George MD GamaMabs Pharma Self Toulouse, France
Genkyotex Vesalius Biocapital Partners Saint-Julien- en-Genevois, France
GamaMabs Pharma Self Toulouse, France
Crescendo Biologics Sofinnova Partners Cambridge, United Kingdom

Portfolio Executives (97)

Name Company Role Deal date Location
Charles Hobley Crescendo Biologics Director, Finance 24-Jul-2023 Cambridge, United Kingdom
Thomas Sandal Crescendo Biologics Vice President of Preclinical Development, Protein Engineering and Research and Development 24-Jul-2023 Cambridge, United Kingdom
Crescendo Biologics Vice President, Business Development 24-Jul-2023 Cambridge, United Kingdom
Crescendo Biologics Chief Operating Officer 24-Jul-2023 Cambridge, United Kingdom
Crescendo Biologics Chief Executive Officer, Chief Financial Officer, CBO & Board Member 24-Jul-2023 Cambridge, United Kingdom

Fund Team Members (27)

Name Investor Fund Fund Location
Stephane Bergez Andera Partners Acto Mezzanine III Paris, France
Stephane Bergez Acto Mezzanine Acto Mezzanine III Paris, France
Andera Partners Paris, France
Andera Partners Paris, France
Edmond de Rothschild Private Equity Luxembourg, Luxembourg

Gilles Nobecourt Affiliated Funds (9)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
BioDiscovery 4 Andera Partners Venture - General Closed 2013
Acto Mezzanine III Andera Partners Mezzanine Closed 2017
BioDiscovery 3 Andera Partners Venture - General Closed 2008
Winch Capital 3 Andera Partners Growth/Expansion Closed 2014
Cabestan Capital Fund Andera Partners Buyout Fully Invested 2012

Gilles Nobecourt FAQs

  • Who is Gilles Nobecourt?

    Dr. Gilles Nobecourt serves as a Partner of the Andera Life Science team at Andera Partners.

  • How much does Gilles Nobecourt typically invest?

    Gilles Nobecourt's median deal size is .

  • What is Gilles Nobecourt’s main position?

    Gilles Nobecourt’s primary position is Partner, Andera Life Science team.

  • What are the contact details for Gilles Nobecourt?

    Gilles Nobecourt’s email address is g. and his phone number is +33 01 .

  • How many active board seats does Gilles Nobecourt hold?

    Gilles Nobecourt holds 5 board seats including Complix, Crescendo Biologics, Evommune, GamaMabs Pharma, and Inotrem.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »